FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity
研究ライブラリに戻る

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

A recent study launched by Eli Lilly and Company aims to explore how fasting duration and withholding of tirzepatide—a popular peptide therapy—impact stomach contents after a meal. The findings could offer valuable insights into the effectiveness and mechanisms of this treatment, particularly for individuals with type 2 diabetes mellitus (T2DM) or those struggling with obesity without T2DM.

Background

Peptide therapies have gained significant traction in recent years due to their potential benefits in managing chronic conditions like diabetes and obesity. Tirzepatide, one such therapy, has shown promise in clinical trials for its ability to control blood sugar levels and promote weight loss. However, understanding how various factors, including fasting times and drug discontinuation, affect the body's response is crucial.

This study, which can be found on ClinicalTrials.gov (NCT07299084), marks an important step in unraveling these dynamics. By using ultrasound technology to measure stomach contents post-meal, researchers aim to provide a clearer picture of how tirzepatide interacts with the digestive system under different conditions.

Key Details

The study is currently active but not recruiting participants, indicating that it has moved past its initial phases and is likely collecting data. Sponsored by Eli Lilly and Company, this Phase 1 clinical trial focuses on evaluating the effect of fasting duration and tirzepatide withholding on stomach content volume in two distinct groups: individuals with T2DM and those without diabetes but who are overweight or obese.

Participants will undergo a test meal scenario where ultrasound scans will be used to measure the amount of food and fluid remaining in their stomachs. The study is designed to shed light on how different fasting periods and pauses in taking tirzepatide influence gastric emptying rates, which could have significant implications for treatment regimens and patient care.

Key Takeaways

  • Understanding Gastric Emptying: This research provides a deeper understanding of how fasting and drug discontinuation affect the rate at which food leaves the stomach.
  • Clinical Utility of Tirzepatide: By examining tirzepatide's effects in both diabetic and non-diabetic obese populations, this study offers critical insights into its broader clinical utility.
  • Regulatory Implications: Data from this trial could influence FDA regulations regarding medication administration guidelines for patients using peptide therapies like tirzepatide.
  • Patient Care Strategies: Insights gained may lead to more personalized treatment plans that account for fasting and drug adherence factors, enhancing patient outcomes.

What This Means

For the peptide community, including researchers, clinicians, and informed consumers, this study underscores the importance of continuous research into how these innovative treatments work in real-world scenarios. Understanding the nuances of gastric emptying under varying conditions can lead to more effective therapeutic strategies and better management of chronic diseases such as diabetes and obesity.

Moreover, the findings could pave the way for future studies that delve even deeper into the mechanisms behind peptide therapies, ultimately contributing to advancements in personalized medicine and improved patient care across various health disciplines.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。